Nimotuzumab: Phase II data

An open-label, Japanese Phase II trial in 37 evaluable patients showed that nimotuzumab plus cisplatin and vinorelbine led to an ORR of 70%. Median PFS was 11.1 months. Furthermore, the combination was tolerable with no infusion reactions, grade 3 skin rash, grade 3 radiation pneumonitis or grade 4 non-hematological toxicity reported. Data were presented at the European Multidisciplinary Cancer meeting in Stockholm. Nimotuzumab is available in the U.S. on a compassionate use basis to treat pediatric glioma and has Orphan Drug designation in the U.S. and Europe to treat adult and pediatric glioma. ...